Earnings ·
Legend Biotech reported second quarter 2026 financial results showing total revenue of $387.5 million, a significant…
LEGNLegend Biotech Corp
Legend Biotech reported second quarter 2026 financial results showing total revenue of $387.5 million, a significant increase from $255.1 million in the prior year period. Collaboration revenue rose to $326.1 million driven by CARVYKTI sales under the Janssen agreement, while license and other revenue reached $61.4 million due to a $56.0 million milestone payment from Janssen. The company achieved net income of $33.2 million compared to a net loss of $125.4 million in Q2 2025. Operating income turned positive at $57.7 million, reversing an operating loss of $21.9 million in the prior year. Legend Biotech also announced the appointment of Alan Bash as Interim Chief Executive Officer and completed a public offering of 7,700,000 American Depositary Shares for net proceeds of approximately $212 million. The company operates in the biotechnology industry, specializing in the discovery, development, manufacturing, and commercialization of cell therapies for oncology.